What is Royalty Pharma's litifilimab — unfunded commitments?

Royalty Pharma (RPRX) reported litifilimab — unfunded commitments of $25.00M in Q1 2026.

What does litifilimab — unfunded commitments mean?

The portion of the total agreed investment for Litifilimab that has not yet been paid out.

Products & Services · Unfunded Commitments

Litifilimab — Unfunded Commitments

Analysis

StatementSegment

CategoryLiquidity

SignalLower is better

VolatilityModerate

First reportedQ1 2026

Last reportedQ1 2026

Rolls up toUnfunded Commitments

How to read this metric

A decrease signals that the firm is fulfilling its funding obligations, while an increase may suggest new milestones or expanded development agreements.

Detailed definition

This metric quantifies the remaining portion of the total contractual capital commitment that has not yet been disbursed...

Peer comparison

Comparable to unfunded capital calls or remaining milestone payment obligations in pharmaceutical partnership contracts.

Metric ID: rprx_segment_litifilimab_unfunded_commitments

Historical Data

1 periods

	Q1 '26
Value	$25.00M

Similar Metrics at Other Companies

The Travelers CompaniesTRV View metric

KKR & Co.KKR View metric

BiogenBIIB View metric

United TherapeuticsUTHR View metric

Merck & Co.MRK View metric

KKR & Co.KKR View metric

Frequently Asked Questions

What is Royalty Pharma's litifilimab — unfunded commitments?: Royalty Pharma (RPRX) reported litifilimab — unfunded commitments of $25.00M in Q1 2026.
What does litifilimab — unfunded commitments mean?: The portion of the total agreed investment for Litifilimab that has not yet been paid out.